Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611345 | 0.94 | KLK7 (0.51) | KLK7GAARAB9ALMNAHTT | |
| SCHEMBL13624511 | 0.87 | MEN1 (0.45) | KLK7GAARAB9ALMNAHTT | |
| SCHEMBL13611346 | 0.87 | MEN1 (0.45) | KLK7GAARAB9ALMNAHTT | |
| SCHEMBL13611343 | 0.84 | KLK7 (0.47) | KLK7GAARAB9ALMNAHTT | |
| SCHEMBL10713248 | 0.80 | RAB9A (0.63) | GAARAB9ALMNAHTTMAPT | |
| SCHEMBL13611338 | 0.79 | CYP1A2 (0.58) | KLK7GAAHTTSIRT5MAPT | |
| SCHEMBL10983201 | 0.79 | KLK7 (0.61) | KLK7GAARAB9AHTTMAPT | |
| SCHEMBL13611340 | 0.76 | KMT2A (0.52) | KLK7GAAMAPTMEN1KMT2A | |
| SCHEMBL13611347 | 0.76 | ATM (0.44) | KLK7GAARAB9ALMNAHTT | |
| SCHEMBL13624512 | 0.76 | ATM (0.44) | KLK7GAARAB9ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078300-A1 | BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130035402-A1 | BIOABSORBABLE POLYESTERAMIDES AND USES THEREOF | BEZWADA BIOMEDICAL, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8367747-B2 | Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof | BEZWADA BIOMEDICAL, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-8309132-B2 | Bioabsorbable polyesteramides and uses thereof | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090292029-A1 | BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF | BEZWADA BIOMEDICAL, L.L.C (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090285896-A1 | BIOABSORBABLE POLYESTERAMIDES AND USES THEREOF | BEZWADA BIOMEDICAL, LLC (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285896-A1 | BIOABSORBABLE POLYESTERAMIDES AND USES THEREOF | PAICS, UROD, PUF60 | KLK7 1948/4885GAA 935/4885RAB9A 2810/4885 |
| US-20090292029-A1 | BIOABSORBABLE POLYMERS FROM BIOABSORBABLE POLYISOCYANATES AND USES THEREOF | PUF60, PFAS, UROD | KLK7 630/4885GAA 64/4885RAB9A 1879/4885 |
| US-20130035402-A1 | BIOABSORBABLE POLYESTERAMIDES AND USES THEREOF | PAICS, UROD, PUF60 | KLK7 1948/4885GAA 935/4885RAB9A 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.